You are here:
Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with inoperable or metastatic HR-Positive, HER2-negative Breast Cancer who have been treated with one or two prior lines of systemic chemotherapy.
No estimate possible yet
Clinical trials
Datopotamab deruxtecan
Oncology
Indication extension
Breast cancer
Daiichi Sankyo
Antibody-drug conjugate
Intracavernous
Injection / infusion solution
Intermural (MSZ)
Centralised (EMA)
Normal trajectory
New therapeutical formulation
No
2024
2025
Single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine)
Er zijn nog geen resultaten bekend uit de TROPION-Breast01 studie.
1 times every 3 weeks
6,0 mg/kg
TROPION-Breast01 (NCT05104866)
Not yet known
There is currently nothing known about off label use.
Yes
Treatment of adult patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations (NCT04656652). Treatment of adult patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy (NCT05374512). Treatment of adult patients with advanced or metastatic NSCLC without actionable genomic alterations whose tumor has high programmed death-ligand 1 (PD-L1) expression and who have not previously received systemic therapy for advanced or metastatic NSCLC (NCT05215340).
Manufacturer
There is currently no further information available.
Understanding of expected market entry of innovative medicines